NovoCure Limited Price Today
NovoCure Limited
NVCR
Healthcare
$3.03B
💰
Market Cap
0
💸
Price to Earnings
$-1.4
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
6 |
Strong Buy |
2 |
Hold |
3 |
Sell |
1 |
Strong Sell |
0 |
NVCR Price Forecast Target
28.6 👉 200.0 +601%
NVCR EPS Forecast
-1.4 👉 -6.2 +353%
Financials
Profit Margin
-34 %
Revenue Growth
-10.5 %
Dividend
$ 0
Held Percent
1.2% - Insiders
85.6% - Institutions
13.2% - Public
Major Fund Holders
-
💰 FMR, LLC $950.5M
-
💰 Capital World Investors $843.5M
-
💰 Vanguard Group Inc $584.4M
-
💰 Baillie Gifford and Company $360.7M
-
💰 Blackrock Inc. $500.7M
Stock Ideas
Howard Marks Portfolio
Meet Howard Marks, the co-founder and lead of Oaktree Capital Management, a Los Angeles-based investment firm that manages roughly $78 billion in investment capital. Marks has an impressive background in distressed debt, high yield bonds, and conver…
Michael Platt Portfolio
Michael Platt is the founder and CEO of BlueCrest Capital Management, a global macro hedge fund with a focus on systematic trading strategies. Prior to starting BlueCrest, Platt worked as a portfolio manager and trader, gaining experience across glo…
Israel Englander Portfolio
Israel Englander, a notable figure in the finance industry, began his journey by obtaining his undergraduate degree from NYU before venturing into trading on the American Stock Exchange (AMEX), where he found early success. In 1989, he went on to es…
Nancy Pelosi Portfolio
Nancy Pelosi is the Speaker of the United States House of Representatives and a savvy investor. Her personal portfolio is heavily weighted towards large-cap tech stocks, such as Apple and Microsoft. She also owns shares in several consumer staples a…📮FAQ
Some Frequently Asked Questions.
The NovoCure Limited industry is Medical Devices
The NovoCure Limited sector is Healthcare
The NovoCure Limited forecasted predicted Price to Earnings PE ratio is -4.6
The NovoCure Limited Price to Earnings PE ratio is 0
The Market Capitalization of NovoCure Limited is $3.03B
There are total of 95420141 float shares with 85.6% held by Institutions and 1.2% held by insiders
The MNovoCure Limited forecasted Earnings per Share EPS is $-6.2
The NovoCure Limited Earnings per Share EPS is -1.4
The NovoCure Limited company has $423584000 gross profits with -34 profit margins
The NovoCure Limited Earnings Growth is 0% with 0% quarterly earnings growth
The NovoCure Limited Revenue is $507660000 with -0.105 revenue growth
The price target for NovoCure Limited stock is $200.0 for the high target and $33.0 for the low target
The consensus analyst recommendations for NovoCure Limited is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for NovoCure Limited is Hold, with the following breakdown:
- Buy: 6
- Strong Buy: 2
- Hold: 3
- Sell: 1
- Strong Sell: 0
The Beta of NovoCure Limited is 0.6
The dividend of NovoCure Limited is $0
The dividend yield of NovoCure Limited is 0%
The biggest institutional and mutual fund holders of NovoCure Limited stock are
- FMR, LLC
- Capital World Investors
- Vanguard Group Inc
- Baillie Gifford and Company
The NovoCure Limited ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0